Transfusion and Laboratory support in Trauma Group Code Red Audit
The aim of the Code Red audit is to monitor and optimise the transfusion support given to patients following major trauma in Scotland
The primary objective is to optimise the transfusion support given to patients following major trauma in Scotland, including the delivery of laboratory services and transfusion support in both the pre-hospital and hospital setting along with the introduction of novel services and approaches.
A standardised data collection form (DCF) was designed and agreed by the Transfusion and Laboratory Support in Trauma Group (TLSTG). Page one of the DCF contains patient information and a unique national code red audit number. Pages 2-4 of the DCF contain anonymised data which will be sent to Alison Glover to enter onto a secure database. Once piloting, this anonymised data will be entered directly onto a web based database (REDcap).
Ethics opinion was obtained from the Lothian Regional Ethics Committee Scientific Advisor and the project was deemed a service evaluation/audit and not therefore requiring full ethics submission. The Caldicott guardian for NHS Lothian has approved the use of the REDcap secure database. Funding for use of the REDcap database was secured from SNBTS
All data is owned by the NHS. Matthew Reed and Alison Glover will maintain the database and act as guardians for the data. The project will initially last 2 years until 30th September 2016 however it is anticipated that the project will be an ongoing one. Data collection is currently underway including retrospective data collection from the introduction of the Code Red protocol at each participating hospital.
Scotland’s main trauma receiving hospitals have agreed to input data into the National Code Red audit and a clinical and transfusion lead has been identified for each centre.
Matthew Reed,Research Team – Members of the Transfusion and Laboratory support in Trauma Group
Scotland’s main trauma receiving hospitals have agreed to input data into the National Code Red audit
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.